Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Cisplatin

Tubulin Modulators

Antimitotic Agents

Concurrent chemoradiotherapy followed by consolidation chemotherapy

Induction chemotherapy followed by concurrent chemoradiotherapy

docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy

docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy

docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.

docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

Jean-Philippe Aussel

Primary Objective:

* To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC (stage IIIA- multiple cN2 or IIIB).

Secondary Objective:

* To estimate efficacy parameters in overall response rate, progression free survival and 1 year survival for each of the two above mentioned arms.

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)

Sanofi

Medical Affairs Study Director

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)	NCT00174772	Lung Neoplasms	docetaxel and c... docetaxel and c...	18 Years - 75 Years	Sanofi
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)	NCT00174772	Lung Neoplasms	docetaxel and c... docetaxel and c...	18 Years - 75 Years	Sanofi
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)	NCT00174772	Lung Neoplasms	docetaxel and c... docetaxel and c...	18 Years - 75 Years	Sanofi

Spots Global Cancer Trial Database for docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy